A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years ...

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Researchers have found "tremendous long-term outcomes" for teenagers who underwent surgery to treat their severe obesity a ...

Wegovy reduced arthritic knee pain in study subjects with high BMI. Unknown: the exact mechanism or whether it would prevent knee replacement surgery.

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

In humans, nasal foralumab modulates immune responses by inducing regulatory-type T cells. Semaglutide is an effective ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is permissible by the FDA.

People who lost a significant amount of weight with semaglutide saw major improvements in osteoarthritis knee pain, research published Wednesday in the New England Journal of Medicine finds.